ReviewSeminars in immunopathology2017
The development of dendritic cell vaccine-based immunotherapies for glioblastoma.
Review in Seminars in immunopathology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- A systematic review of immunotherapy in high-grade glioma: learning from the past to shape future perspectives.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2024Pooled it
- Integrating biocomputational techniques for vaccine development for glioblastoma multiforme: a possible way of enhancing precision.Frontiers in immunology · 2026Review
- CD8+ T Cells Primed by Antigenic Peptide-Pulsed B Cells or Dendritic Cells Generate Similar Anti-Tumor Response.Vaccines · 2025Article
- Prospects and applications of NK therapy in the treatment of gliomas (Review).Oncology reports · 2025Review
- FLT3L combined with GM-CSF induced dendritic cells drive broad tumor-specific CD8Frontiers in immunology · 2025Article
- Efficacy of cell-based immunotherapies on patients with glioma: an umbrella review of systematic reviews and meta-analysis protocol.BMJ open · 2023Article
- The Current Status, Challenges, and Future Potential of Therapeutic Vaccination in Glioblastoma.Pharmaceutics · 2023Review
- p53 inhibits the Urea cycle and represses polyamine biosynthesis in glioma cell lines.Metabolic brain disease · 2023Article
- Pharmacological inhibition of the ubiquitin-specific protease 8 effectively suppresses glioblastoma cell growth.Open life sciences · 2023Article
- Immunotherapy associated central nervous system complications in primary brain tumors.Frontiers in oncology · 2023Review
- Advancements in dendritic cell vaccination: enhancing efficacy and optimizing combinatorial strategies for the treatment of glioblastoma.Frontiers in neurology · 2023Review
- Cell-based immunotherapy of glioblastoma multiforme.Oncology letters · 2022Review
- DC-Derived Exosomes for Cancer Immunotherapy.Cancers · 2021Review
- LncRNA SAMMSON Knockdown Inhibits the Malignancy of Glioblastoma Cells by Inactivation of the PI3K/Akt Pathway.Cellular and molecular neurobiology · 2021Article
- Making a Cold Tumor Hot: The Role of Vaccines in the Treatment of Glioblastoma.Frontiers in oncology · 2021Review
- USP5 Sustains the Proliferation of Glioblastoma Through Stabilization of CyclinD1.Frontiers in pharmacology · 2021Article
- DC-Based Vaccines for Cancer Immunotherapy.Vaccines · 2020Review
- Preventing Lethal Prostate Cancer with Diet, Supplements, and Rx: Heart Healthy Continues to Be Prostate Healthy and "First Do No Harm" Part III.Current urology reports · 2020Review
- Blockade of STAT3 Signaling Contributes to Anticancer Effect of 5-Acetyloxy-6,7,8,4'-Tetra-Methoxyflavone, a Tangeretin Derivative, on Human Glioblastoma Multiforme Cells.International journal of molecular sciences · 2019Article
- IRGM promotes glioma M2 macrophage polarization through p62/TRAF6/NF-κB pathway mediated IL-8 production.Cell biology international · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In this review, we focus on the biologic advantages of dendritic cell-based vaccinations as a therapeutic strategy for cancer as well as preclinical and emerging clinical data associated with such approaches for glioblastoma patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.